EGFR and non-small cell lung carcinoma: In conclusion, our case demonstrated that upfront chemotherapy plus PD-1 inhibitor might be an option for some NSCLC patients of BM harboring EGFR exon 20 insertion and high PD-L1 expression/high TMB.